Market watch: Nuvei, VerticalScope, Magnet Forensics
Nuvei posts strong Q4, 2021 earnings as VerticalScope, Magnet see mixed results.
Montréal
Somm acquires last-minute restaurant reservation app Dinr to move beyond wine recommendation
Somm describes Dinr deal as “part of a bigger vision” for the wine-focused startup.
Clinia closes $5 million to scale B2B health search infrastructure
Montréal startup aims to be “first point of entry for health searches.”
Zymeworks co-founder, former CEO Ali Tehrani joins Amplitude Ventures as venture partner
Tehrani aims to leverage his Zymeworks learnings to help other Canadian biotech firms grow.
Haivision to acquire France’s Aviwest to expand low latency video solutions
Aviwest is Haivision’s second acquisition post-IPO.
Hopper continues acquisition spree with Parisian airline travel tech Smooss
Hopper looks to bolster its B2B offering as it expands into new verticals.
Busbud closes $14 million CAD, acquires Recorrido to fuel Latin American expansion
Chilean energy firm COPEC’s venture arm led the round.
Mila partners with AI Sweden to bolster AI R&D in Canada and Sweden
AI Sweden has established a physical presence in Montréal.
Bank of Montreal commits $100 million to launch lending program for Black entrepreneurs
Black entrepreneurs can receive loans of up to $250,000.
Paper secures $343 million CAD with US schools drawn to its remote tutoring tech
Paper doubled the number of students on its platform to two million since last year.
Following recent merger, Startup Montréal announces program to spur late-stage growth
The Government of Québec has committed $6.5 million to the program.
Oncology innovators Canexia Health, Imagia merge, raise $20 million
Imagia CEO Geralyn Ochab will lead the combined companies.
Montréal Inc and Bonjour Startup Montréal merge, become Startup Montréal
The new org will have “a substantially greater impact,” says Startup Montréal.
Axya raises $3.9 million in seed extension to scale deployment of supply chain software
The initial round closed in March and raised $1.5 million.
Canadian biotech leader Clarissa Desjardins secures $63 million CAD for Congruence Therapeutics
PerkinElmer and Ipsen purchased two of Desjardins’ previous companies.